Bioactive Phytochemicals from Sesame Oil Processing By-products

Mekky, Reham Hassan; Hegazy, Mostafa M.; Cádiz-Gurrea, María de la Luz; Fernández-Ochoa, Álvaro; Carretero, Antonio Segura

doi:10.1007/978-3-030-63961-7_9-1

Cited by 1 publication

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sankar's et al stated that the decrease in LDL-C and TC may be due to high levels of MUFA in SO [28]. SO lignans belong to phytochemical family [41]. A human study showed that sesamin, a lignan in SO, significantly reduced LDL-C [42].…”

Section: Lipid Profilementioning

confidence: 99%

The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

Vahedi

Atefi

Entezari

et al. 2022

Trials

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. There is strong evidence that dyslipidemia and other cardio-metabolic disorders are highly prevalent in patients with NAFLD. This trial aimed at examining the effect of sesame oil (SO) in the context of a weight loss program on lipid profile, blood pressure, and anthropometric indices in women with NAFLD. Methods This randomized, double-blind, controlled trial was carried out on 60 women with NAFLD. Subjects were randomly assigned to the SO group (n = 30) and sunflower oil (SFO) group (n = 30), each person consuming 30 g of oil per day for 12 weeks. All the participants received a hypocaloric diet (− 500 kcal/day) during the study. Lipid profile, blood pressure, and anthropometric indices were assessed at pre- and post-intervention phases. Results In total, 53 participants completed the study. Following 12 weeks of intervention, anthropometric indices (p < 0.001) and systolic blood pressure (SBP) (p < 0.05) were significantly decreased in both groups and diastolic blood pressure (DBP) was significantly decreased in So group (p = 0.03). There was no significant change in lipid profile in both groups (p > 0.05). After adjusting for confounders, DBP (p = 0.031) and total cholesterol (TC) divided by high-density lipoprotein cholesterol (HDL-C) (p = 0.039) in the SO group were significantly reduced compared to the SFO group (p < 0.05). Conclusions The present clinical trial revealed that SO and SFO may not differently affect anthropometric indices, SBP, and lipid profile except for TC/HDL-C. In addition, SO may be effective in improvement of DBP and TC/HDL-C compared to the SFO group. Trial registration Ethical approval of this trial was obtained at Isfahan University of Medical Sciences with the reference number of IR.MUI.RESEARCH.REC.1399.548 (https://ethics.research.ac.ir/ProposalCertificateEn.php?id=158942&Print=true&NoPrintHeader=true&NoPrintFooter=true&NoPrintPageBorder=true&LetterPrint=true), and it was registered before the start of the patient recruitment on December 12th, 2020 in the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20140208016529N6.

show abstract

Section: Lipid Profilementioning

confidence: 99%